Protection against malaria by Plasmodium yoelii sporozoite surface protein 2 linear peptide induction of CD4+ T cell- and IFN-gamma-dependent elimination of infected hepatocytes.
about
Body iron delocalization: the serious drawback in iron disorders in both developing and developed countriesA hybrid multistage protein vaccine induces protective immunity against murine malariaCircumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malariaImaging effector functions of human cytotoxic CD4+ T cells specific for Plasmodium falciparum circumsporozoite protein.CD8+ T cells specific for a malaria cytoplasmic antigen form clusters around infected hepatocytes and are protective at the liver stage of infection.Fusion of antigen to a dendritic cell targeting chemokine combined with adjuvant yields a malaria DNA vaccine with enhanced protective capabilitiesWhy functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model.Simultaneous induction of multiple antigen-specific cytotoxic T lymphocytes in nonhuman primates by immunization with a mixture of four Plasmodium falciparum DNA plasmidsInterleukin-10 responses to liver-stage antigen 1 predict human resistance to Plasmodium falciparum.Mice with a selective impairment of IFN-gamma signaling in macrophage lineage cells demonstrate the critical role of IFN-gamma-activated macrophages for the control of protozoan parasitic infections in vivoCD4-positive and CD8-positive cytotoxic T lymphocytes contribute to human papillomavirus type 16 E6 and E7 responsesInfectivity of Plasmodium berghei sporozoites delivered by intravenous inoculation versus mosquito bite: implications for sporozoite vaccine trialsCD4(+) T-cell- and gamma interferon-dependent protection against murine malaria by immunization with linear synthetic peptides from a Plasmodium yoelii 17-kilodalton hepatocyte erythrocyte protein.Antibodies against thrombospondin-related anonymous protein do not inhibit Plasmodium sporozoite infectivity in vivoA modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hostsA statistical interaction between circumsporozoite protein-specific T cell and antibody responses and risk of clinical malaria episodes following vaccination with RTS,S/AS01EAntibody responses to 43 and 48 kDa antigens of blood-stage Plasmodium berghei in Balb/c mice.A small peptide (CEL-1000) derived from the beta-chain of the human major histocompatibility complex class II molecule induces complete protection against malaria in an antigen-independent mannerPre-erythrocytic-stage immune effector mechanisms in Plasmodium spp. infections.Development of two monoclonal antibodies against Plasmodium falciparum sporozoite surface protein 2 and mapping of B-cell epitopesMurine immune responses to liver-stage antigen 1 protein FMP011, a malaria vaccine candidate, delivered with adjuvant AS01B or AS02AAllicin enhances host pro-inflammatory immune responses and protects against acute murine malaria infection.Stability of interferon-gamma and interleukin-10 responses to Plasmodium falciparum liver stage antigen 1 and thrombospondin-related adhesive protein immunodominant epitopes in a highland population from Western KenyaPresentation of hepatocellular antigens.A retrospective evaluation of the role of T cells in the development of malaria vaccine.Immune responses against protozoan parasites: a focus on the emerging role of Nod-like receptors.A Recombinant Chimeric Ad5/3 Vector Expressing a Multistage Plasmodium Antigen Induces Protective Immunity in Mice Using Heterologous Prime-Boost Immunization Regimens.Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes.Interferon-γ responses to Plasmodium falciparum vaccine candidate antigens decrease in the absence of malaria transmission.A linear peptide containing minimal T- and B-cell epitopes of Plasmodium falciparum circumsporozoite protein elicits protection against transgenic sporozoite challenge.Class II-restricted protective immunity induced by malaria sporozoites.Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial
P2860
Q26824358-EB7E0DCC-3D65-44F1-91BA-4642B046E325Q28730779-6F5FE5FB-4B67-4D71-B728-6FBD2F6228DAQ28744170-6BD8593D-CBC3-4740-9851-09BEEB992D8CQ30497914-122EF3DE-EC39-4716-BB16-4B418E2B8C9DQ30555356-FF474C52-3A29-4C75-BA76-4062587CCC65Q31152863-BD33B184-5C8C-4FC3-91FD-F3437247C3B9Q33587443-CCD0C419-F8A5-4B8F-807E-DB50F4FA0D3BQ33761524-D910A4A3-686B-4BA5-8B3D-0515803D63F5Q33876788-FFE466EC-C97B-4CED-9ED4-9338EB187935Q33915925-7784A714-C3E4-42D6-BBBB-9C0D82643B93Q33997723-8E1AC230-B862-4C9A-A63A-2960BEC11A38Q34001568-F6ECE6EF-0D83-45DB-AE7D-1C31891A6E0CQ34002308-4771DE14-EF7D-4A58-95AB-577023934522Q34004839-A89C2918-F378-4915-9707-0142473B1459Q34261339-14669D0A-AE49-4F60-B270-6EE056B32629Q34541330-DCFAA57A-DF7F-4A73-ADA4-CEBE744FB693Q34847990-8A3552F7-A89F-43EF-B383-30D82B280296Q35124515-87E06BFE-1AAC-48C3-BB79-9BCABE8B6809Q35211719-738E5C66-A7CA-4232-8754-A65A1F6C0EF4Q35553683-604712B8-C3E2-45A8-80AD-F800C670CE69Q35689159-9BA684D0-FF16-447F-B85C-069351AE596AQ36320072-458146E5-883B-4D80-BF22-CC2C073E8E95Q36791117-FC8536FD-9697-483E-B90F-5561E4D0F01CQ36870035-0191434E-2950-4917-A9FA-CABDD9CA070CQ37640209-C9F453BB-2F97-4333-BC86-B480680A44CEQ38794791-AF9227B9-5C34-4724-AC5C-91E5D1334C61Q39441716-6E50E828-C951-40DF-AD09-05308A38AA6FQ40205403-05685092-A484-4C54-87E3-3CBD920F88CEQ40368142-58FFD814-89B3-4D3D-BB14-929215003529Q41058932-2C0AD0FE-810E-46D1-8E78-2DD073BF0BEAQ41825623-9B6C4070-B1BC-4349-830D-F4298B94E724Q42754531-D7D203BE-FAC8-417F-B3DC-EB9D187156DC
P2860
Protection against malaria by Plasmodium yoelii sporozoite surface protein 2 linear peptide induction of CD4+ T cell- and IFN-gamma-dependent elimination of infected hepatocytes.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Protection against malaria by ...... ation of infected hepatocytes.
@en
Protection against malaria by ...... ation of infected hepatocytes.
@nl
type
label
Protection against malaria by ...... ation of infected hepatocytes.
@en
Protection against malaria by ...... ation of infected hepatocytes.
@nl
prefLabel
Protection against malaria by ...... ation of infected hepatocytes.
@en
Protection against malaria by ...... ation of infected hepatocytes.
@nl
P2093
P1476
Protection against malaria by ...... ation of infected hepatocytes.
@en
P2093
Charoenvit Y
Corradin G
De La Vega P
P304
P407
P577
1996-11-01T00:00:00Z